Prophylaxis of First Hemorrhage from Esophageal Varices
Author Information
Author(s): PROVA Study Group
Hypothesis
Does endoscopic sclerotherapy, propranolol, or both effectively prevent the first variceal hemorrhage in cirrhotic patients?
Conclusion
The study found no significant benefit of sclerotherapy or propranolol in preventing variceal bleeding in cirrhotic patients.
Supporting Evidence
- Variceal bleeding occurred in a similar proportion in all groups.
- The mortality rate without variceal bleeding was significantly higher in the sclerotherapy groups.
- The total mortality rate showed no significant difference between treatment groups.
Takeaway
Doctors tested if certain treatments could stop bleeding in patients with liver problems, but they found that these treatments didn't help.
Methodology
Randomized multicenter trial comparing sclerotherapy, propranolol, both, and a control group in cirrhotic patients with esophageal varices.
Potential Biases
Potential bias in bleeding definitions and treatment allocation.
Limitations
The trial was stopped early due to excess mortality in the sclerotherapy group.
Participant Demographics
Cirrhotic patients with esophageal varices, 819 screened, 286 enrolled.
Statistical Information
P-Value
0.002
Confidence Interval
1.45 to 5.22
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website